REG - Intnl. Biotechnology - Update on Fund Management arrangements

International Biotechnology TrustAnnouncement

20/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231120:nRST3995Ta&default-theme=true

RNS Number : 3995T  Intl. Biotechnology Trust PLC  20 November 2023

20 November 2023

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

("IBT" or the "Company")

 

Update on Fund Management arrangements and related services

 

 

Further to the Company's previous announcements, the Board is pleased to
report that with effect from 20 November 2023:

 

·      Schroder Unit Trusts Limited ("SUTL") has been appointed as the
Company's Fund Manager and Alternative Investment Fund Manager ("AIFM").

 

·      Ailsa Craig and Marek Poszepczynski have joined Schroder
Investment Management Limited ("SIML", a sister company to SUTL) from SV
Health Partners LLP and will continue as the Company's portfolio managers.

 

·      The Depositary agreement with Northern Trust Company has been
terminated and the Company's new Depositary will be HSBC Bank plc.

 

·      The Company's website is www.schroders.com/IBT
(http://www.schroders.com/IBT) .

 

·      SIML has been appointed as Company Secretary and can be contacted
at amcompanysecretary@schroders.com (mailto:amcompanysecretary@schroders.com)
.

 

·      The registered office address of the Company is set to change to
1 London Wall Place, London EC2Y 5AU.

 

For further information, please contact:

Fund Manager - SUTL

Augustine Chipungu      +44 (0) 20 7658 2106

Corporate Broker - Deutsche Numis

Nathan Brown                +44 (0)20 7260 1426 / +44 (0)7795
964 870

Financial PR - KL Communications

Charles Gorman            +44 (0)20 3995 6673 / +44 (0) 7795 977
967

 

LEI: 213800N1QUJ744P76D11

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDGPGQUGUPWGUC